Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118326 · ClinicalTrials.gov registry record · Phase 1
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00118326: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT00118326 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00118326, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Colony-stimulating factors, such as G-CSF, cause the body to make blood cells. Giving G-CSF to the donor may help the body make more stem cells that can be collected for bone marrow transplant and may cause fewer side effects in the patient after the transplant. PURPOSE: This phase I/II trial is studying the side effects of donor bone marrow transplant and to see how well it works in treating young patients with cancer or a non-cancerous disease.
Interventions
- BIOLOGICAL filgrastim
- PROCEDURE allogeneic bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-08 |
| Est. Completion | 2007-05 |
| Phase | Phase 1 |
What the finished NCT00118326 record still lists
NCT00118326 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which filgrastim is the first listed.
NCT00118326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00118326 about?
NCT00118326 is a clinical study titled "Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease". RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Colony-stimulating factors, such as G-CSF, cause the body to make blood cells. Giving G-CSF to the donor may help the body make more stem ...
What is the current status of trial NCT00118326?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-08. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00118326?
The interventions under investigation include: filgrastim (BIOLOGICAL), allogeneic bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00118326?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia